An integrative approach to determine the best behavioral and biological markers of methylphenidate

Journal of Integrative Neuroscience

Volumn 6, Issue 1, 2007, Pages 105-140

  Hermens, Daniel F ^a   Cooper, Nicholas J ^b   Clark, Richard C ^c   Debrota, David ^d   Clarke, Simon D ^e   Williams, Leanne M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Brain Resource Company   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d ELI LILLY AND COMPANY   (United States)

^e WESTMEAD HOSPITAL   (Australia)

Author keywords

Arousal; Attention; Controlled trial; Methylphenidate; Psychophysiology

Indexed keywords

METHYLPHENIDATE;

ADULT; ALERTNESS; ARTICLE; ATTENTION; AUTONOMIC NERVOUS SYSTEM FUNCTION; BEHAVIOR; BLOOD PRESSURE; BRAIN FUNCTION; COGNITION; COMPUTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTERVIEW; MALE; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; PSYCHOPHYSIOLOGY; REACTION TIME; SCORING SYSTEM; SENSITIVITY ANALYSIS; THETA RHYTHM;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; ASSOCIATION LEARNING; ATTENTION; BEHAVIOR; BIOLOGICAL MARKERS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOICE BEHAVIOR; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; HUMANS; LINEAR MODELS; MALE; MAZE LEARNING; MENTAL PROCESSES; METHYLPHENIDATE; NEUROPSYCHOLOGICAL TESTS; REACTION TIME;

EID: 34248202587     PISSN: 02196352     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0219635207001441     Document Type: Article

References (98)

1. Alexander DM, Johnston P, Cooper T, Trengrove C, Gordon E, Separating individual skin conductance responses in a short interstimulus-interval paradigm, J Neurosci Meth 156:111-118, 2005.
2. Aman MG, Vamos M, Werry JS, Effects of methylphenidate in normal adults with reference to drug action in hyperactivity, Aust NZ J Psych 18:86-88, 1984.
3. Anderer P, Saletu B, Semlitsch HV, Pascual-Marqui RD, Perceptual and cognitive event-related potentials in neuropsychopharmacology: Methodological aspects and clinical applications (pharmaco-ERP topography and tomography), Method Find Exp Clin Pharmacol 24 121-137, 2002.
4. Andersen SL, Stimulants and the developing brain, Trends Pharmacol Sci 26:237-243, 2005.
5. Bedard AC, Ickowicz A, Logan GD, Hogg-Johnson S, Schachar R, Tannock R, Selective inhibition in children with attention-deficit hyperactivity disorder off and on stimulant medication, J Abnorm Child Psych 31:315-327, 2003.
6. Bedard AC, Ickowicz A, Tannock R, Methylphenidate improves Stroop naming speed, but not response interference, in children with attention deficit hyperactivity disorder, J Child Adol Psych 12:301-309, 2002.
7. Bedard AC, Martinussen R, Ickowicz A, Tannock R, Methylphenidate improves visual-spatial memory in children with attention-deficit/ hyperactivity disorder, J Am Acad Child Adol Psych 43 260-268, 2004.
8. Berchou R, Chayasirisobhon S, Green V, Mason K, The pharmacodynamic properties of lorazepam and methylphenidate drugs on event-related potentials and power spectral analysis in normal subjects, Clin Electroenc 17:176-180, 1986.
9. Biederman J, Spencer T, Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder, Biol Psychiat 46:1234-1242, 1999.
10. Bond A, Lader M, The use of analogue scales in rating subjective feelings, Br J Med Psych 47:211-218, 1974.
11. Brown RT, Sexson SB, Effects of methylphenidate on cardiovascular responses in attention deficit hyperactivity disordered adolescents, J Adol Health Care 10: 179-183, 1989.
12. Brown RT, Wynne ME, Slimmer LW, Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning, J Clin Psych 45:473-476, 1984.
13. Brumaghim JT, Klorman R, Methylphenidate's effects on paired-associate learning and event-related potentials of young adults, Psychophysiology 35:73-85, 1998.
14. Callaway E, Halliday R, Naylor H, Hyperactive children's event-related potentials fail to support underarousal and maturational-lag theories, Arch Gen Psych 40:1243-1248, 1983.
15. Camp-Bruno JA, Herting RL, Cognitive effects of milacemide and methylphenidate in healthy young adults, Psychopharmacology 115 46-52, 1994.
16. Clark CR, Geffen GM, Geffen LB, Role of monoamine pathways in attention and effort: Effects of clonidine and methylphenidate in normal adult humans, Psychopharmacology 90:35-39, 1986.
17. Clark CR, Geffen GM, Geffen LB, Role of monoamine pathways in the control of attention: Effects of droperidol and methylphenidate in normal adult humans, Psychopharmacology 90:28-34, 1986.
18. Clark CR, Paul RH, Williams LM, Arns M, Fallahpour K, Handmer C, Gordon E, Standardized assessment of cognitive functioning during development and aging using an automated touchscreen battery, Arch Clin Neuropsych 21:449-467, 2006.
19. Clarke AR, Barry RJ, Bond D, McCarthy R, Selikowitz M, Effects of stimulant medications on the EEG of children with attention-deficit/ hyperactivity disorder, Psychopharmacology 164:277-284, 2002.
20. Clarke AR, Barry RJ, McCarthy R, Selikowitz M, Brown CR, Croft RJ, Effects of stimulant medications on the EEG of children with attention-deficit/hyperactivity disorder predominantly inattentive type, Int J Psychophysiol 47:129-137, 2003.
21. Coons HW, Peloquin LJ, Klorman R, Bauer LO, Ryan RM, Perlmutter RA, Salzman LF, Effect of methylphenidate on young adult's vigilance and event-related potentials, Electroenceph Clin Neuro 51 373-387, 1981.
22. Cooper NJ, Keage H, Hermens D, Williams LM, Debrota D, Clark CR, Gordon E, The dose-dependent effect of methylphenidate on performance, cognition and psychophysiology, J Integ Neurosci 4:123-144, 2005.
23. Coull JT, Neural correlates of attention and arousal: Insights from electrophysiology, functional neuroimaging and psychopharmacology, Prog Neurobiol 55:343-361, 1998.
24. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ, Dopamine transporter density in patients with attention deficit hyperactivity disorder, Lancet 354:2132-2133, 1999.
25. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW, Effects of methylphenidate on spatial working memory and planning in healthy young adults, Psychopharmacology 131:196-206, 1997.
26. Evans RW, Gualtieri CT, Amara I, Methylphenidate and memory: Dissociated effects in hyperactive children, Psychopharmacology 90 211-216, 1986.
27. Gordon E, Genomics and neuromarkers are both required in the era of brain-related "Personalized Medicine", Personalized Medicine, May 2007.
28. Gordon E, Cooper N, Rennie C, Hermens D, Williams LM, Integrative neuroscience: The role of a standardized database, Clin EEG Neurosci 36:64-75, 2005.
29. Gratton G, Coles MG, Donchin E, A new method for off-line removal of ocular artifact, Electroenceph Clin Neuro 55:468-484, 1983.
30. Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn J, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells K, Medication treatment strategies in the MTA Study: Relevance to clinicians and researchers, J Am Acad Child Adol Psych 35:1304-1313, 1996.
31. Gronwall DM, Paced auditory serial-addition task: A measure of recovery from concussion, Percept Mot Skills 44:367-373, 1977.
32. Halliday R, Callaway E, Naylor H, Gratzinger P, Prael R, The effects of stimulant drugs on information processing in elderly adults, J Gerontol 41:748-757, 1986.
33. Hermens DF, Cooper NJ, Kohn MR, Clarke SD, Gordon E, Williams LM, Predicting stimulant medication response in ADHD: Evidence from an integrated profile of neuropsychological, psychophysiological and clinical factors, J Integ Neurosci 4:107-121, 2005.
34. Hermens DF, Kohn MR, Clarke SD, Gordon E, Williams LM, Sex differences in adolescent ADHD: Findings from concurrent EEG and EDA, Clin Neurophysiol 116:1455-1463, 2005.
35. Hermens DF, Rowe DL, Gordon E, Williams LM, Integrative neuroscience approach to predict ADHD stimulant response, Expert Rev Neurotherapeutics 6:753-763, 2006.
36. Hermens DF, Soei EXC, Clarke SD, Kohn MR, Gordon E, Williams LM, Resting EEG theta activity predicts cognitive performance in attention-deficit hyperactivity disorder, Pediatr Neurol 32:248-256, 2005.
37. Hermens DF, Williams LM, Clarke S, Kohn M, Cooper N, Gordon E, Responses to methylphenidate in adolescent AD/HD: Evidence from concurrently recorded autonomic (EDA) and central (EEG and ERP) measures, Int J Psychophysiol 58:21-33, 2005.
38. Hink RF, Fenton WH Jr, Tinklenberg JR, Pfefferbaum A, Kopell BS, Vigilance and human attention under conditions of methylphenidate and secobarbital intoxication: An assessment using brain potentials, Psychophysiology 15:116-125, 1978.
39. Klimesch W, EEG alpha and theta oscillations reflect cognitive and memory performance: A review and analysis, Brain Res Rev 29 169-195, 1999.
40. Koelega HS, Stimulant drugs and vigilance performance: A review, Psychopharmacology 111:1-16, 1993.
41. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA, Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate, Exp Clin Psychopharm 6:367-374, 1998.
42. Langleben DD, Monterosso J, Elman I, Ash B, Krikorian G, Austin G, Effect of methylphenidate on Stroop Color-Word task performance in children with attention deficit hyperactivity disorder, Psych Res 141(3):315-320, 2006.
43. Lazzaro I, Anderson J, Gordon E, Clarke S, Leong J, Meares R, Single trial variability within the P300 (250-500 ms) processing window in adolescents with attention deficit hyperactivity disorder, Psych Res 73:91-101, 1997.
44. Loo SK, Hopfer C, Teale PD, Reite ML, EEG correlates of methylphenidate response in ADHD: Association with cognitive and behavioral measures, J Clin Neurophysiol 21:457-464, 2004.
45. Loo SK, Teale PD, Reite ML, EEG correlates of methylphenidate response among children with ADHD: A preliminary report, Biol Psych 45 1657-1660, 1999.
46. Losier BJ, McGrath PJ, Klein RM, Error patterns on the continuous performance test in non-medicated and medicated samples of children with and without ADHD: A meta-analytic review, J Child Psych Psych 37:971-987, 1996.
47. Mackworth NH, The breakdown of vigilance during prolonged visual search, Q J Exp Psychol 1:6-21, 1948.
48. Mesulam MM, A cortical network for directed attention and unilateral neglect, Ann Neurol 10:309-325, 1981.
49. Monastra VJ, Monastra DM, George S, The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder, Appl Psychophysiol Biofeed 27:231-249, 2002.
50. Naylor H, Halliday R, Callaway E, The effect of methylphenidate on information processing, Psychopharmacology 86:90-95, 1985.
51. Oades RD, The role of noradrenaline in tuning and dopamine in switching between signals in the CNS, Neurosci Biobehav Rev 9:261-282, 1985.
52. Oken BS, Kishiyama SS, Salinsky MC, Pharmacologically induced changes in arousal: Effects on behavioral and electrophysiologic measures of alertness and attention, Electroenceph Clin Neuro 95 359-371, 1995.
53. Ozdag MF, Yorbik O, Ulas UH, Hamamcioglu K, Vural O, Effect of methylphenidate on auditory event related potential in boys with attention deficit hyperactivity disorder, Int J Pediatr Otorhinolaryngol 68:1267-1272, 2004.
54. Parrott AC, Performance tests in human psychopharmacology (1): Test reliability and standardization, Hum Psychopharm 6:1-9, 1991.
55. Parrott AC, Performance tests in human psychopharmacology (2): Content validity, criterion validity, and face validity, Hum Psychopharm 6:91-98, 1991.
56. Paul RH, Lawrence J, Williams LM, Clark CR, Cooper N, Gordon E, The validity of "IntegNeuro": A new computerized and standardized battery of neurocognitive tests, Int J Neurosci 115:1549-1567, 2005.
57. Peloquin LJ, Klorman R, Effects of methylphenidate on normal children's mood, event-related potentials, and performance in memory scanning and vigilance, J Abnorm Psych 95:88-98, 1986.
58. Pivik RT, Broughton RJ, Coppola R, Davidson RJ, Fox N, Nuwer MR, Guidelines for the recording and quantitative analysis of electroencephalographic activity in research contexts, Psychophysiology 30:547-558, 1993.
59. Pliszka SR, McCracken JT, Maas JW, Catecholamines in attention-deficit hyperactivity disorder: Current perspectives, J Am Acad Child Adol Psych 35:264-272, 1996.
60. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ, Dextroamphetamine, its cognitive and behavioral effects in normal and hyperactive boys and normal men, Arch Gen Psych 37 933-943, 1980.
61. Rapoport JL, Inoff-Germain G, Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: Update 2002, J Atten Disord 6:57-60, 2002.
62. Rapport MD, Moffitt C, Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects, Clin Psych Rev 22:1107-1131, 2002.
63. Riccio CA, Waldrop JJ, Reynolds CR, Lowe P, Effects of stimulants on the continuous performance test (CPT): Implications for CPT use and interpretation, J Neuropsychiatry Clin Neurosci 13:326-335, 2001.
64. Sachdev PS, Trollor JN, How high a dose of stimulant medication in adult attention deficit hyperactivity disorder, Aust NZ J Psych 34 645-650, 2000.
65. Saletu B, Anderer P, Saletu-Zyhlarz GM, EEG topography and tomography (LORETA) in the classification and evaluation of the pharmacodynamics of psychotropic drugs, Clin EEG Neurosci 37:66-80, 2006.
66. Sangal RB, Sangal JM, Attention-deficit/hyperactivity disorder: Using P300 topography to choose optimal treatment, Expert Rev Neurotherapeutics 6:1429-1437, 2006.
67. Satterfield JH, Cantwell DP, Proceedings: CNS function and response to methylphenidate in hyperactive children, Psychopharmacol Bull 10:36-37, 1974.
68. Seifert J, Scheuerpflug P, Zillessen KE, Fallgatter A, Warnke A, Electrophysiological investigation of the effectiveness of methylphenidate in children with and without ADHD, J Neural Transm 110:821-829, 2003.
69. Smithee JA, Klorman R, Brumaghim JT, Borgstedt AD, Methylphenidate does not modify the impact of response frequency or stimulus sequence on performance and event-related potentials of children with attention deficit hyperactivity disorder, J Abnorm Child Psych 26 233-245, 1998.
70. Solanto MV, Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: A review and integration, Beh Brain Res 94:127-152, 1998.
71. Solanto MV, Conners CK, A dose-response and time-action analysis of autonomic and behavioral effects of methylphenidate in attention deficit disorder with hyperactivity, Psychophysiol 19:658-667, 1982.
72. Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, Bonab AA, Fischman AJ, In Vivo neuroreceptor imaging in attention-deficit/ hyperactivity disorder: A focus on the dopamine transporter, Biol Psych 57:1293-1300, 2005.
73. Spielberger C, Gorsuch R, Lushene R, Vagg P, Facobs G, Manual for the state-trait anxiety inventory, STAI (Form Y), Consulting Psychologists Press, Palo Alto, CA, 1983.
74. Tannock R, Schachar R, Methylphenidate and cognitive perseveration in hyperactive children, J Child Psych Psych 33:1217-1228, 1992.
75. Tannock R, Schachar RJ, Carr RP, Chajczyk D, Effects of methylphenidate on inhibitory control in hyperactive children, J Abnorm Child Psych 17:473-491, 1989.
76. Taylor MJ, Voros JG, Logan WJ, Malone MA, Changes in event-related potentials with stimulant medication in children with attention deficit hyperactivity disorder, Biol Psych 36:139-156, 1993.
77. Tucha O, Prell S, Mecklinger L, Bormann-Kischkel C, Kubber S, Linder M, Walitza S, Lange KW, Effects of methylphenidate on multiple components of attention in children with attention deficit hyperactivity disorder, Psychopharmacol 185:315-326, 2006.
78. Tukey JW, Ciminera JL, Heyse JF, Testing the statistical certainty of a response to increasing doses of a drug, Biometrics 41 295-301, 1985.
79. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ, Cognitive enhancing effects of modafinil in healthy volunteers, Psychopharmacol 165:260-269, 2003.
80. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ, Relative lack of cognitive effects of methylphenidate in elderly male volunteers, Psychopharmacol 168:455-464, 2003.
81. Urman R, Ickowicz A, Fulford P, Tannock R, An exaggerated cardiovascular response to methylphenidate in ADHD children with anxiety, J Child Adol Psychopharm 5:29-37, 1995.
82. Uttl B, Graf P, Richter LK, Verbal paired associates tests limits on validity and reliability, Arch Clin Neuropsych 17:567-581, 2002.
83. Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, Gabrieli JD, Selective effects of methylphenidate in attention deficit hyperactivity disorder: A functional magnetic resonance study, Proc Natl Acad Sci USA 95:14494-14499, 1998.
84. Verbaten MN, Overtoom CC, Koelega HS, Swaab-Barneveld H, van der Gaag RJ, Buitelaar J, van Engeland H, Methylphenidate influences on both early and late ERP waves of ADHD children in a continuous performance test, J Abnorm Child Psych 22:561-578, 1994.
85. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D, Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain, J Neurosci 21:RC121-201.
86. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N, Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate, Am J Psych 155 1325-1331, 1998.
87. Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas NR, Zhu W, Swanson JM, Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma, Psychopharmacol 166 264-270, 2003.
88. Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, Logan J, Gatley SJ, Pappas N, Wong C, Vaska P, Zhu W, Swanson JM, Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain, Am J Psych 16 1173-1180, 2004.
89. Volkow ND, Wang GJ, Gatley SJ, Fowler JS, Ding YS, Logan J, Hitzemann R, Angrist B, Lieberman J, Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects, Psychopharmacol 123 26-33, 1996.
90. Weingartner H, Rapoport JL, Buchsbaum MS, Bunney WE Jr, Ebert MH, Mikkelsen EJ, Caine ED, Cognitive processes in normal and hyperactive children and their response to amphetamine treatment, J Abnorm Psych 89:25-37, 1980.
91. Wilens TE, Biederman J, Lerner M, Concerta Study Group, Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: Results from a one-year follow-up study, J Clin Psychopharm 24 36-41, 2004.
92. Wilens TE, Spencer TJ, The stimulants revisited, Child Adol Psych Clin N Am 9:573-603, 2000.
93. Williams LM, Simms E, Clark CR, Paul RH, Rowe D, Gordon E, The test-retest reliability of a standardized neurophysiological and neuropsychological test battery: "NeuroMarker", Int J Neurosci 115:1605-1630, 2005.
94. Williams LM, Palmer D, Liddell BJ, Song L, Gordon E, The "when" and "where" of perceiving signals of threat versus non-threat, NeuroImage 31:458-467, 2006.
95. Winsberg BG, Javitt DC, Silipo GS, Electrophysiological indices of information processing in methylphenidate responders, Biol Psych 42:434-445, 1997.
96. Yerkes RM, Dodson JD, The relation of strength of stimulus to rapidity of habit formation, J Comp Neurol Psych 18:459-482, 1908.
97. Zahn TP, Abate F, Little BC, Wender PH, Minimal brain dysfunction, stimulant drugs, and autonomic nervous system activity, Arch Gen Psych 32:381-387, 1975.
98. Zahn TP, Rapoport JL, Thompson CL, Autonomic and behavioral effects of dextroamphetamine and placebo in normal and hyperactive prepubertal boys, J Abnorm Child Psych 8:145-160, 1980.